Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1894 in Healthy Subjects
NCT07414602Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dermatitis comparing SHR-1894 Injection Group with SHR-1894 Injection Placebo Group (2 arms). Primary endpoint: Adverse Events. Started Mar 2026; status: recruiting.
02
Drugs
SHR-1894
03
Conditions
dermatitis
Beyond the preview
Go deeper on NCT07414602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414602.